Blog for healthcare thought leaders and thinkers driven by passion to improve healthcare dialogue in India.
Author Archive
Guest Blog: India and drug safety : Latest PVig attempt showing promise

Guest Blog: India and drug safety : Latest PVig attempt showing promise

India seems to be making slow but sure progress towards reversing its abysmal track record in pharmacovigilance – medical jargon for monitoring the safety of marketed medicines. The country has reported 33,702 adverse drug reactions (ADRs),  side-effects arising from a host of marketed drugs, as of December 21, 2012,  according to data shared by the National...
Guest Blog: India & med tech : the sub-optimal state

Guest Blog: India & med tech : the sub-optimal state

  Public-funded institutions and government agencies are increasingly supporting India’s nascent medical technology sector either as research or funding partners. Yet, what the state is so keen to help sow is it also equally willing to nurture? Not really. First, here are some instances of public funding or research partnerships of indigenous companies. -Mysore-based Skanray,...
Guest Column: India’s move to vanilla generics : Don’t hold your breath

Guest Column: India’s move to vanilla generics : Don’t hold your breath

By now, the news that India wants to move away from branded generics and encourage vanilla generics to bring down drug prices has gone around the world.  But all those who think a structural reform of the Indian drug industry is around the corner : stop. And breathe. First, for the record, the news. The...
Guest Column: India and clinical trials: in the dock?

Guest Column: India and clinical trials: in the dock?

India’s Supreme Court has expressed concern at the conduct of clinical trials  asking the government to provide information on the number of trials being conducted, adverse event reports, deaths, compensation to subjects and so on.  Call me an optimist but this could be one of the best things to have happened to the sector in recent years....
Guest Column: India and drug pricing : the illusion of closure

Guest Column: India and drug pricing : the illusion of closure

A group of ministers (GoM) has put its weight behind a market-based pricing mechanism for 348 essential drugs, a departure from the current practice of pricing a dated list of 74 drugs based on their manufacturing costs. The GoM decision might suggest that closure to a long-pending issue isn’t far away. But to my mind,...
Guest Column: Antibiotic resistance in India : Right problem, wrong solution

Guest Column: Antibiotic resistance in India : Right problem, wrong solution

The Indian drugs regulator is keen on tighter controls on the retail of antibiotics. This is to curb abuse and drug resistance, a menace of ever-growing proportions.  A just cause, of course. But the method that it seeks to employ for the purpose is questionable. The Times of India reported this week that the regulator has proposed the...
Guest Column:Ernst & Young on universal healthcare : money or soul?

Guest Column:Ernst & Young on universal healthcare : money or soul?

An Ernst & Young report released last week in tie-up with industry chamber FICCI reckons that public or government funding of healthcare should be raised to between 3.7 per cent and 4.5 per cent of gross domestic product from 1 per cent at present to achieve universal healthcare over a period of ten years. See here....